NFSG
LCTX icon

Newbridge Financial Services Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Newbridge Financial Services Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$5 – 1161
2024
Q3 		$5 Hold
5
– – ﹤0.01% 652
2024
Q2 		$5 Hold
5
– – ﹤0.01% 1079
2024
Q1 		$7 Hold
5
– – ﹤0.01% 1169
2023
Q4 		$5 Hold
5
– – ﹤0.01% 1115
2023
Q3 		$6 Hold
5
– – ﹤0.01% 1278
2023
Q2 		$7 Hold
5
– – ﹤0.01% 1342
2023
Q1 		$8 Hold
5
– – ﹤0.01% 1401
2022
Q4 		$6 Hold
5
– – ﹤0.01% 1434
2022
Q3 		$0 Hold
5
– – ﹤0.01% 1431
2022
Q2 		$0 Buy
+5
New +$7 ﹤0.01% 1447

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Newbridge Financial Services Group's LCTX Position: Q4 2024 in Review

Newbridge Financial Services Group sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 5 shares — an estimated $5 sold.

Newbridge Financial Services Group first reported a position in LCTX in Q2 2022 and held it in 10 quarters. The position peaked at $8 in Q1 2023. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

  • Newbridge Financial Services Group reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 5 Lineage Cell Therapeutics shares in Q4 2024, an estimated $5.
  • Newbridge Financial Services Group first reported a position in Lineage Cell Therapeutics in Q2 2022 and held it in 10 quarters.
  • Newbridge Financial Services Group's Lineage Cell Therapeutics position peaked at $8 in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Newbridge Financial Services Group's 13F filing for Q4 2024, filed 28 Jan 2025.